“The new protocol for Severely Ill COVID-19 patients is

New Post Public Reply Private Reply Replies (2) Message Board
TechGuru
836
Quote:
“The new protocol for Severely Ill COVID-19 patients is for 342 patients, double blinded with 2:1 ratio. Patients enrolled in this trial are expected to be administered leronlimab for two weeks with the primary endpoint being the mortality rate at 14 days”

Some might be asking what is behind these numbers, why 2:1 ratio ?? Why 342 patients ??

First of all, trials are kept to a minimum of patients for expedience and economic reasons (well, not always). To ensure that neither too few nor too many patients are included in the study, the sample size is planned in advance. To calculate how many patients will be needed there are two main factors:

The level of significance: This is the probability of obtaining a statistically significant test result, even in the case that there are no differences. This is normally taken as 2.5% for so called one-tailed tests or 5% for two-tailed tests.

The statistical power: this is the probability of identifying a real difference with the statistical test. Normally taken as 80% or 90%.

Now, why a 2:1 ratio? Normal trials are a 1:1 ratio and a 2:1 complicates analysis and extends the number of patients needed. There are several possible reasons for this:

- Patients are more likely to join two arm trials with placebo when their odds of receiving active treatment are greater.
- A high drop-out rate is expected in one arm (allocating more patients to the arm with a high drop-out rate allows greater power for a “per-protocol” analysis.
- Gathering additional safety information: A larger sample size in the active group gives more power to detect adverse events
- Learning curves: Some new technologies have a learning curve. Allocating more patients to the new technology reduces the effect of the learning curve on the final trial result
- Humanitarian reasons: If the product is thought to help patients more will be exposed to the beneficial drug than the placebo arm (I think this is the reason in this case).

The good news is that these trials (unequal allocation ratios) are normally aimed at vindicating treatments (“confirmatory trials”) !!!. That is, the philosophy is to confirm something.

Now, why 342 patients? First of all, with 2:1 ratio 12% more patients are needed. This would indicate a 1:1 design for 306 patients (is possible to work with a 2:1 but complicates things unnecessarily). I will attempt to explain the number simply, but unfortunately, will need to use some mathematical jargon. Just go to the conclusion if you don’t like math (nothing wrong with it )

If we used a two-sided design with a power of 90% and 5% significance. The question is: how many people will be needed? To answer we need to know what we want to obtain and whether the information we have already is firm or not. In simple words, let me " affirm " the following for the sake of explanation (I am making up the numbers): In USA the death rate for COVID patients going into ventilators is 80%. We (FDA) will approve a drug that reduces this rate to 70%. Or, I could say: In the USA the rate of death of persons going into ventilators is in average 80% with a normal distribution and a standard deviation of so and so, I will approve the drug only if the mean of the resulting death rate is such with so and so deviation. This will produce a different calculation for the patients needed (roughly double).

Not knowing if FDA already has a solid number (for example China and other countries statistics, or USA so far) of just assumed a distribution. Let’s work with the latter (distribution is known, not the number.) We have then from a formula (or tables) that for approximately 305 patients the difference of means is 0.15 (266 from 0.9:0.75, 322 for 0.85:0.7, 350 for 0.8:0.65).

For those interested a very useful document is: Sample Size Tables for Clinical Studies David Machin Michael Campbell. Can download PDF (warning, don’t download the WinZip Driver but use the green bar that say “Download PDF” down below).

https://epdf.pub/sample-size-tables-for-clini...udies.html

Conclusion : If my assumptions are correct (5% significance and 0.9 power), FDA is expecting that Leronimab will reduce the death rate in a factor of approximately 0.15 for approval.

I am making lots of assumptions here like type of statistical distribution and parameters and the results are just approximations for illustrative purposes for what to expect as we start to see the results of Leronlimab coming.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cybersecurity's AI Tailwind Meets a Brutal Market Test

Updated Category News Views 89

Security software caught a bid while the rest of the tape was getting kicked down the stairs. That contrast is the whole story: investors saw Palo Alto Networks deliver a strong fiscal first quarter and raise its fiscal 2027 outlook, then decided cyber defense may be one of the few technology budgets companies cannot casually postpone. With AI helping attackers locate and...

Continue Reading
Flair's New Aviation Alliance Offers Options, Not Orders

Updated Category News Views 13

Aircraft shortages have a funny way of turning vague partnerships into very useful insurance policies. Flair Airlines, Phoenix Aviation Capital and Avia Solutions Group announced a Strategic Commercial Cooperation Agreement on Nov. 19, 2026, and the sensible reading is straightforward: the Canadian value carrier wants more ways to solve capacity and operational problems...

Continue Reading
Liquidity Services Faces a Brutal Revenue Reality Check

Updated Category News Views 33

A 19.17% opening haircut is the market ringing the fire alarm, not politely clearing its throat. Liquidity Services reported fiscal fourth-quarter revenue of $106.4 million, roughly 10% below the prior-year quarter, and shareholders got hit hard on November 19, 2026. That reaction is ugly, but it is not mysterious. When a company built around moving surplus inventory...

Continue Reading
PCS Rental Prep Is About Control Before Distance Hits

Updated Category News Views 19

A vacant house can turn into a long-distance headache with startling speed. For military homeowners preparing for a PCS move, the useful point in Rhonda Leahy's guidance is not glamorous: settle the boring operational stuff before the moving boxes, travel orders, and new-duty-station chaos swallow the calendar. Renting out a former home is not merely collecting enough...

Continue Reading
Appian Survey Flags AI Aloneware Maintenance Drag Risk

Updated Category News Views 10

A bot can spit out a feature before lunch, then leave a repair bill nobody budgeted for. That is the uncomfortable issue behind Appian's new research on AI-assisted software development: speed is easy to celebrate, while ownership gets shoved into a dark corner until something breaks. Appian said on November 20, 2026, that two-thirds of surveyed AI decision-makers and IT...

Continue Reading
Chargeback AI Still Has a Costly Last-Mile Problem

Updated Category News Views 41

A corrected headline is a small wrinkle, but the underlying chargeback mess is not. Chargeflow and Juniper Research surveyed 121 senior executives at U.S. and U.K. businesses with at least $100 million in annual gross merchandise value, and the useful takeaway is painfully clear: merchants are putting AI on the label without rebuilding the machinery underneath. That...

Continue Reading
Childhood Nutrition Advice That Lowers Mealtime Stress

Updated Category News Views 31

A toddler surviving on three bites Tuesday is not a verdict on the family table. That plain idea sits at the center of pediatric expert Kathy Shirazi’s guidance on childhood nutrition, and frankly, it deserves more oxygen than another impossible-looking lunchbox photo. In the HelloNation article released November 20, 2026, Shirazi, MD, MPH, FAAP, urges parents to judge...

Continue Reading
Anduin Opens Its Investor Portal Beyond Early Users

Updated Category News Views 50

Private-market paperwork has long been a swamp of portals, PDFs, email chains, and somebody chasing down a wire change at the worst possible moment. Anduin is taking a swing at that mess by opening its Investor Portal to all customers after building it with leading asset managers and operating it with their investors. The pitch is sensible: give limited partners one...

Continue Reading
Mindgruve's Tech Hire Puts Sightline Growth in Focus

Updated Category News Views 67

Agency technology hires usually land with all the thunder of a stapler dropping, but this one deserves a closer look. Mindgruve has named Steve Terjeson vice president of technology, handing a former WPP Choreograph executive the job of leading its software development and data engineering teams. The assignment is not vague: push AI innovation, make the proprietary...

Continue Reading
CVS Puts Youth Soccer Stories on Its Store Shelves

Updated Category News Views 42

Two kids with real community ties just got a megaphone most grown-ups never receive. CVS Pharmacy has named Caroline, 9, of Holmes Beach, Florida, and Zoe, 12, of Los Angeles, as the first grand-prize winners of its Home Team Heroes youth soccer contest. Each player’s selected nonprofit soccer organization will receive a $25,000 grant, while their stories will appear on...

Continue Reading

Top 5 Most Recently Viewed Articles

Celebrating Friendship and Joy: POP MART at Macy's Parade

Updated Category News Views 385

Celebration of Pop Culture at Macy's Thanksgiving Parade With excitement in the air, POP MART is gearing up for a remarkable debut at the iconic Macy's Thanksgiving Day Parade. This year marks an enchanting chapter as the brand unveils its unique float, themed "Friendsgiving in POP CITY," showcasing an array of beloved characters from the POP MART universe. The event will...

Continue Reading
NEC X Launches New Opportunity for Future Startups

Updated Category News Views 438

NEC X Invites Applications for Innovative Venture Programs NEC X, a dynamic venture studio based in Silicon Valley, is now opening its doors for applications to the Elev X! Ignite program. This initiative is geared towards transforming promising early-stage startups into fully developed businesses ready for investment. With the potential for up to $200,000 in equity...

Continue Reading
Palatin Technologies Unveils Innovative Approaches for Inflammation

Updated Category News Views 316

Palatin Technologies Unveils Innovative Approaches for Inflammation Palatin Technologies, Inc. (NYSE American: PTN), a pioneering biopharmaceutical company, has recently showcased significant advancements in the treatment of inflammatory diseases. The firm, known for its first-in-class medicines based on melanocortin receptor modulation, delivered compelling data during...

Continue Reading
Drumstick Unveils Unique Peanut Butter Sundae Cone Flavor

Updated Category News Views 623

Drumstick Launches Game-Changing Peanut Butter Sundae Cones A warm welcome to all peanut butter aficionados! Drumstick®, one of America's beloved sundae cone brands, has introduced a delightful new flavor aimed squarely at peanut butter lovers. This exciting launch brings amazing peanut butter and chocolate peanut butter sundae cones to grocery stores across the nation....

Continue Reading
Michael Saylor's Perspective on Quantum Computing and Bitcoin

Updated Category News Views 98

Michael Saylor's Vision on Quantum Computing's Impact on Bitcoin Michael Saylor, the Executive Chairman of Strategy Inc. (NASDAQ: MSTR), has made a strong claim regarding the potential influence of quantum computing on Bitcoin. On social media, he emphasized his belief that quantum computing will not undermine Bitcoin, the leading cryptocurrency, but instead enhance its...

Continue Reading